WO2018147710A1 - 이미다조퀴놀린계열 물질을 포함하는 나노에멀젼 및 이의 용도 - Google Patents
이미다조퀴놀린계열 물질을 포함하는 나노에멀젼 및 이의 용도 Download PDFInfo
- Publication number
- WO2018147710A1 WO2018147710A1 PCT/KR2018/001891 KR2018001891W WO2018147710A1 WO 2018147710 A1 WO2018147710 A1 WO 2018147710A1 KR 2018001891 W KR2018001891 W KR 2018001891W WO 2018147710 A1 WO2018147710 A1 WO 2018147710A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- oil
- nanoemulsion
- agonist
- imidazoquinoline
- Prior art date
Links
- 239000007908 nanoemulsion Substances 0.000 title claims abstract description 68
- SQQXRXKYTKFFSM-UHFFFAOYSA-N chembl1992147 Chemical compound OC1=C(OC)C(OC)=CC=C1C1=C(C)C(C(O)=O)=NC(C=2N=C3C4=NC(C)(C)N=C4C(OC)=C(O)C3=CC=2)=C1N SQQXRXKYTKFFSM-UHFFFAOYSA-N 0.000 title claims abstract description 44
- 229940124669 imidazoquinoline Drugs 0.000 title claims abstract description 44
- 239000000463 material Substances 0.000 title claims abstract description 30
- 239000000556 agonist Substances 0.000 claims abstract description 43
- 239000002671 adjuvant Substances 0.000 claims abstract description 34
- 229960005486 vaccine Drugs 0.000 claims abstract description 18
- 239000003921 oil Substances 0.000 claims description 71
- 235000019198 oils Nutrition 0.000 claims description 54
- 108010060825 Toll-Like Receptor 7 Proteins 0.000 claims description 32
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 32
- 108010060752 Toll-Like Receptor 8 Proteins 0.000 claims description 31
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims description 31
- 239000000243 solution Substances 0.000 claims description 30
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical group C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims description 27
- 229960002751 imiquimod Drugs 0.000 claims description 26
- 102000036639 antigens Human genes 0.000 claims description 23
- 108091007433 antigens Proteins 0.000 claims description 23
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 23
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 22
- 239000000427 antigen Substances 0.000 claims description 22
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 22
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 21
- 229940031439 squalene Drugs 0.000 claims description 21
- 239000004094 surface-active agent Substances 0.000 claims description 21
- 239000003446 ligand Substances 0.000 claims description 18
- 239000003970 toll like receptor agonist Substances 0.000 claims description 18
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 229920000136 polysorbate Polymers 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 10
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 9
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 9
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 9
- 101000643024 Homo sapiens Stimulator of interferon genes protein Proteins 0.000 claims description 9
- 239000005642 Oleic acid Substances 0.000 claims description 9
- -1 Polyoxyethylene Polymers 0.000 claims description 9
- 102100035533 Stimulator of interferon genes protein Human genes 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 7
- 229950010550 resiquimod Drugs 0.000 claims description 7
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 claims description 7
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 7
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 6
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 claims description 6
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 6
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 claims description 6
- 239000002480 mineral oil Substances 0.000 claims description 6
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 6
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims description 6
- 229930182490 saponin Natural products 0.000 claims description 6
- 150000007949 saponins Chemical class 0.000 claims description 6
- 229930003799 tocopherol Natural products 0.000 claims description 6
- 239000011732 tocopherol Substances 0.000 claims description 6
- 229950006418 dactolisib Drugs 0.000 claims description 5
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 claims description 5
- 230000003993 interaction Effects 0.000 claims description 5
- 235000010446 mineral oil Nutrition 0.000 claims description 5
- 150000003904 phospholipids Chemical class 0.000 claims description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 5
- 229950011111 sumanirole Drugs 0.000 claims description 5
- RKZSNTNMEFVBDT-MRVPVSSYSA-N sumanirole Chemical compound C([C@H](C1)NC)C2=CC=CC3=C2N1C(=O)N3 RKZSNTNMEFVBDT-MRVPVSSYSA-N 0.000 claims description 5
- 235000013311 vegetables Nutrition 0.000 claims description 5
- FHJATBIERQTCTN-UHFFFAOYSA-N 1-[4-amino-2-(ethylaminomethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol Chemical compound C1=CC=CC2=C(N(C(CNCC)=N3)CC(C)(C)O)C3=C(N)N=C21 FHJATBIERQTCTN-UHFFFAOYSA-N 0.000 claims description 4
- QSPOQCXMGPDIHI-UHFFFAOYSA-N 2-amino-n,n-dipropyl-8-[4-(pyrrolidine-1-carbonyl)phenyl]-3h-1-benzazepine-4-carboxamide Chemical compound C1=C2N=C(N)CC(C(=O)N(CCC)CCC)=CC2=CC=C1C(C=C1)=CC=C1C(=O)N1CCCC1 QSPOQCXMGPDIHI-UHFFFAOYSA-N 0.000 claims description 4
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 claims description 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 4
- 102000002689 Toll-like receptor Human genes 0.000 claims description 4
- 108020000411 Toll-like receptor Proteins 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 230000000840 anti-viral effect Effects 0.000 claims description 4
- 125000002091 cationic group Chemical group 0.000 claims description 4
- 229940124670 gardiquimod Drugs 0.000 claims description 4
- XMHIUKTWLZUKEX-UHFFFAOYSA-N hexacosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O XMHIUKTWLZUKEX-UHFFFAOYSA-N 0.000 claims description 4
- 239000000411 inducer Substances 0.000 claims description 4
- 229960004232 linoleic acid Drugs 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- NNNVXFKZMRGJPM-KHPPLWFESA-N sapienic acid Chemical compound CCCCCCCCC\C=C/CCCCC(O)=O NNNVXFKZMRGJPM-KHPPLWFESA-N 0.000 claims description 4
- 235000010384 tocopherol Nutrition 0.000 claims description 4
- 229960001295 tocopherol Drugs 0.000 claims description 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 3
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- FKMHSNTVILORFA-UHFFFAOYSA-N 2-[2-(2-dodecoxyethoxy)ethoxy]ethanol Chemical class CCCCCCCCCCCCOCCOCCOCCO FKMHSNTVILORFA-UHFFFAOYSA-N 0.000 claims description 3
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 claims description 3
- 241000251468 Actinopterygii Species 0.000 claims description 3
- 235000021357 Behenic acid Nutrition 0.000 claims description 3
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 claims description 3
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 3
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 claims description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 3
- 108010034143 Inflammasomes Proteins 0.000 claims description 3
- 239000005639 Lauric acid Substances 0.000 claims description 3
- 235000021353 Lignoceric acid Nutrition 0.000 claims description 3
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 claims description 3
- 235000021314 Palmitic acid Nutrition 0.000 claims description 3
- 235000021319 Palmitoleic acid Nutrition 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 3
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- 229920004890 Triton X-100 Polymers 0.000 claims description 3
- 239000013504 Triton X-100 Substances 0.000 claims description 3
- ZBNRGEMZNWHCGA-PDKVEDEMSA-N [(2r)-2-[(2r,3r,4s)-3,4-bis[[(z)-octadec-9-enoyl]oxy]oxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC ZBNRGEMZNWHCGA-PDKVEDEMSA-N 0.000 claims description 3
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 3
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 3
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 3
- 229940114079 arachidonic acid Drugs 0.000 claims description 3
- 235000021342 arachidonic acid Nutrition 0.000 claims description 3
- 229940116226 behenic acid Drugs 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 230000001086 cytosolic effect Effects 0.000 claims description 3
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims description 3
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 3
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 3
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 claims description 3
- 150000002170 ethers Chemical class 0.000 claims description 3
- FARYTWBWLZAXNK-WAYWQWQTSA-N ethyl (z)-3-(methylamino)but-2-enoate Chemical compound CCOC(=O)\C=C(\C)NC FARYTWBWLZAXNK-WAYWQWQTSA-N 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 229940067606 lecithin Drugs 0.000 claims description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- 229950007627 motolimod Drugs 0.000 claims description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 3
- 229920000847 nonoxynol Polymers 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- 229960002446 octanoic acid Drugs 0.000 claims description 3
- 229920002114 octoxynol-9 Polymers 0.000 claims description 3
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 3
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 3
- 229940068977 polysorbate 20 Drugs 0.000 claims description 3
- 229940068968 polysorbate 80 Drugs 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 229940035044 sorbitan monolaurate Drugs 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims description 3
- IEORSVTYLWZQJQ-UHFFFAOYSA-N 2-(2-nonylphenoxy)ethanol Chemical compound CCCCCCCCCC1=CC=CC=C1OCCO IEORSVTYLWZQJQ-UHFFFAOYSA-N 0.000 claims description 2
- 108090000288 Glycoproteins Proteins 0.000 claims description 2
- 102000003886 Glycoproteins Human genes 0.000 claims description 2
- UWHZIFQPPBDJPM-FPLPWBNLSA-M Vaccenic acid Natural products CCCCCC\C=C/CCCCCCCCCC([O-])=O UWHZIFQPPBDJPM-FPLPWBNLSA-M 0.000 claims description 2
- 235000021322 Vaccenic acid Nutrition 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 239000002158 endotoxin Substances 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- OYHQOLUKZRVURQ-AVQMFFATSA-N linoelaidic acid Chemical compound CCCCC\C=C\C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-AVQMFFATSA-N 0.000 claims description 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- UWHZIFQPPBDJPM-BQYQJAHWSA-N trans-vaccenic acid Chemical compound CCCCCC\C=C\CCCCCCCCCC(O)=O UWHZIFQPPBDJPM-BQYQJAHWSA-N 0.000 claims description 2
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 claims 4
- NXMUXTAGFPJGTQ-UHFFFAOYSA-N decanoic acid;octanoic acid Chemical compound CCCCCCCC(O)=O.CCCCCCCCCC(O)=O NXMUXTAGFPJGTQ-UHFFFAOYSA-N 0.000 claims 1
- 239000012646 vaccine adjuvant Substances 0.000 abstract description 11
- 229940124931 vaccine adjuvant Drugs 0.000 abstract description 11
- 239000002612 dispersion medium Substances 0.000 abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 30
- 239000008055 phosphate buffer solution Substances 0.000 description 26
- 206010028980 Neoplasm Diseases 0.000 description 25
- 108010058846 Ovalbumin Proteins 0.000 description 21
- 201000011510 cancer Diseases 0.000 description 20
- 229940092253 ovalbumin Drugs 0.000 description 20
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 18
- 150000002632 lipids Chemical class 0.000 description 18
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 16
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 239000012528 membrane Substances 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 210000001744 T-lymphocyte Anatomy 0.000 description 14
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 12
- 102100037850 Interferon gamma Human genes 0.000 description 10
- 108010074328 Interferon-gamma Proteins 0.000 description 10
- 229910019142 PO4 Inorganic materials 0.000 description 10
- 235000012000 cholesterol Nutrition 0.000 description 9
- 230000028327 secretion Effects 0.000 description 9
- 230000004913 activation Effects 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 210000004443 dendritic cell Anatomy 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 210000002865 immune cell Anatomy 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 108010028921 Lipopeptides Proteins 0.000 description 6
- 230000007969 cellular immunity Effects 0.000 description 6
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 235000017709 saponins Nutrition 0.000 description 5
- ZLJJDBSDZSZVTF-LXOQPCSCSA-N Trehalose-6,6'-dibehenate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC)O1 ZLJJDBSDZSZVTF-LXOQPCSCSA-N 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 210000004979 bone marrow derived macrophage Anatomy 0.000 description 4
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 4
- 238000002296 dynamic light scattering Methods 0.000 description 4
- 230000004727 humoral immunity Effects 0.000 description 4
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010040721 Flagellin Proteins 0.000 description 3
- 101001125026 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 2 Proteins 0.000 description 3
- 102100029441 Nucleotide-binding oligomerization domain-containing protein 2 Human genes 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229940037003 alum Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000028996 humoral immune response Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000003549 soybean oil Substances 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- REEGNIYAMZUTIO-MGSMBCBTSA-N (2s)-2-[[(3r)-3-decanoyloxytetradecanoyl]amino]-3-[(2r,3r,4r,5s,6r)-3-[[(3r)-3-decanoyloxytetradecanoyl]amino]-4-[(3r)-3-decanoyloxytetradecanoyl]oxy-6-(hydroxymethyl)-5-phosphonooxyoxan-2-yl]oxypropanoic acid Chemical compound CCCCCCCCCCC[C@@H](OC(=O)CCCCCCCCC)CC(=O)N[C@H](C(O)=O)CO[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCC)[C@H]1NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCC REEGNIYAMZUTIO-MGSMBCBTSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108010084333 N-palmitoyl-S-(2,3-bis(palmitoyloxy)propyl)cysteinyl-seryl-lysyl-lysyl-lysyl-lysine Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- RFCBNSCSPXMEBK-INFSMZHSSA-N c-GMP-AMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 RFCBNSCSPXMEBK-INFSMZHSSA-N 0.000 description 2
- 230000009702 cancer cell proliferation Effects 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- RRTPWQXEERTRRK-UHFFFAOYSA-N n-[4-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)oxybutyl]octadecanamide Chemical compound C1=CC=CC2=C3N(OCCCCNC(=O)CCCCCCCCCCCCCCCCC)C(CCCC)=NC3=C(N)N=C21 RRTPWQXEERTRRK-UHFFFAOYSA-N 0.000 description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 230000007420 reactivation Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000010686 shark liver oil Substances 0.000 description 2
- 229940069764 shark liver oil Drugs 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 231100000057 systemic toxicity Toxicity 0.000 description 2
- 239000003760 tallow Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229940021747 therapeutic vaccine Drugs 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 235000019149 tocopherols Nutrition 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 2
- YZAZXIUFBCPZGB-FJEDDJBMSA-N (e)-octadec-9-enoic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O.CCCCCCCC\C=C\CCCCCCCC(O)=O YZAZXIUFBCPZGB-FJEDDJBMSA-N 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- GAJTUMASULCSDK-KTKRTIGZSA-N 2-[(Z)-octadec-9-enoxy]benzamide Chemical compound C(CCCCCCC\C=C/CCCCCCCC)OC1=C(C(=O)N)C=CC=C1 GAJTUMASULCSDK-KTKRTIGZSA-N 0.000 description 1
- JYCQQPHGFMYQCF-UHFFFAOYSA-N 4-tert-Octylphenol monoethoxylate Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCO)C=C1 JYCQQPHGFMYQCF-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002884 Laureth 4 Polymers 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 238000000719 MTS assay Methods 0.000 description 1
- 231100000070 MTS assay Toxicity 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101100481584 Mus musculus Tlr1 gene Proteins 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 108700006640 OspA Proteins 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229940124615 TLR 7 agonist Drugs 0.000 description 1
- 229940124614 TLR 8 agonist Drugs 0.000 description 1
- WPMWEFXCIYCJSA-UHFFFAOYSA-N Tetraethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCO WPMWEFXCIYCJSA-UHFFFAOYSA-N 0.000 description 1
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 1
- ISXSJGHXHUZXNF-LXZPIJOJSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate;hydrochloride Chemical compound Cl.C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 ISXSJGHXHUZXNF-LXZPIJOJSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940060265 aldara Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940032077 cervical cancer vaccine Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- PDXMFTWFFKBFIN-XPWFQUROSA-N cyclic di-AMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 PDXMFTWFFKBFIN-XPWFQUROSA-N 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- HABLENUWIZGESP-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O.CCCCCCCCCC(O)=O HABLENUWIZGESP-UHFFFAOYSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000011488 interferon-alpha production Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940062711 laureth-9 Drugs 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 229920006395 saturated elastomer Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940038774 squalene oil Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000010698 whale oil Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
Definitions
- the present invention is directed to nanoemulsions comprising an oil layer comprising an imidazoquinoline-based toll-like receptor 7 or 8 agonist and oil, and their use as adjuvants and vaccines.
- Vaccine adjuvant is an adjuvant adjuvant and activates immune cells and plays an important role in the prevention and treatment of infectious diseases vaccines and chemotherapy.
- Aluminum salts aluminum salt, alum
- squalene nanoemulsions MF59, AS03, AF03, etc.
- MF59, AS03, AF03, etc. humoral immune responses that contribute to antibody responses.
- nanoemulsion-based adjuvants are limited to influenza vaccines.
- an adjuvant composition comprising a complex of a negatively charged polymer and a toll-like receptor agonist, and a collagen-based or gelatin-based material. These adjuvant compositions are disclosed to have multi-stage phase transition properties with temperature changes.
- imidazoquinoline-based drugs e.g., Imiquimod, Resiquimod, Dactolisib, Dactolisib, Gardiquimod) Quimod
- Sumanirole sumanirol
- imidazoquinoline-based materials have many difficulties in dispersing in aqueous solution due to their molecular structure.
- imiquimod R837
- DMSO dimethyl methoxysulfoxide
- imiquimod has been commercialized in a cream formulation (product name: Aldara® from 3M) with various surfactants.
- imidazoquinoline-based drugs in salt form eg, HCl
- HCl salt form
- the present inventors dissolve the imidazoquinoline toll-like receptor 7 or 8 agonist, which is difficult to solubilize in aqueous solution, into oil using a dispersion medium material and prepare the oil mixture in the form of nanoemulsion, thereby making it difficult to solubilize the imidazoquinoline series.
- the present invention was developed by developing an immunoactivating substance having both the immunological properties and the immunological properties of oil-based nanoemulsions, and finding that it can be used not only for humoral immunity but also for adjuvant and vaccine for improving cellular immunity. Completed.
- the present invention provides a nanoemulsion comprising an oil layer comprising an imidazoquinoline-based toll-like receptor 7 or 8 agonist and an oil.
- imidazoquinoline-based toll-like receptor 7 or 8 agonist may be dispersed in a nano-sized oil layer.
- At least one selected from the group consisting of the surfactant and the immunoactivating material may be coated on the outside of the oil layer.
- imidazoquinoline-based toll-like receptor 7 or 8 agonist may be immimod (Imiquimod), Resiquimod (Resiquimod), Dactolisib, Cardiquimod (Gardiquimod), Sumanirole (Sumanirole) ), Motolimod, 3M-052, S-34240, 852, 854-A from 3M, and their derivatives.
- the oil may be selected from the group consisting of fish derived oil, animal derived oil, vegetable derived oil, tocopherol, mineral oil, and castor oil,
- imidazoquinoline-based toll-like receptor 7 or 8 agonists and oil may be included in a weight ratio of 0.1: 100 to 1:50.
- the imidazoquinoline-based toll-like receptor 7 or 8 agonist may further include a mediator to help the lipophilic interaction between the oil.
- the mediator is myristic oleic acid, palmitoleic acid, sapienic acid (Sapienic acid), oleic acid, Elaidic acid (Elaidic acid), Vaccenic acid, linoleic acid, linoleicidic acid (Linoelaidic acid) , Alpha-linoleic acid, arachidonic acid, eicosapentaenoic acid, erucic acid, docosahexaenonic acid, caprylic acid, capric acid, capric acid acid), Lauric acid, Myristic acid, Palmitic acid, Stearic acid, Arachidic acid, Behenic acid, Lignoceric acid, and It may be selected from the group consisting of cerotic acid.
- the mediator material may be included in a weight ratio of 0.1: 10 to 10: 0.1 with the imidazoquinoline-based toll-like receptor 7 or 8 agonist.
- the surfactant is a polyoxyethylene sorbitan ester surfactant (Tween), including polysorbate 20 and polysorbate 80; Copolymers comprising at least one of ethylene oxide (EO), propylene oxide (PO) and butylene oxide (BO); Octosinol including Triton X-100 and t-octylphenoxypolyethoxyethanol; (Octylphenoxy) polyethoxyethanol; Phosphatidylcholine (lecithin) phospholipids including phosphatidylethanolaniline, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, phosphatidic acid, sphingomyelin and cardiolipin; Nonylphenol ethoxylate; Polyoxyethylene patty ethers derived from lauryl, cetyl and oleyl alcohols including triethyleneglycol monolauryl ethers; And sorbitan esters
- the immunoactivator may be a toll-like receptor agonist (TLR), a saponin, an antiviral peptide, an inflammasome inducer, a NOD ligand, a CDS ligand ( cytosolic DNA sensor ligands), stimulator of interferon genes (STING) ligands, and cationic lipids.
- TLR toll-like receptor agonist
- saponin a saponin
- an antiviral peptide an antiviral peptide
- an inflammasome inducer a NOD ligand
- CDS ligand cytosolic DNA sensor ligands
- STING stimulator of interferon genes
- an adjuvant composition comprising the nanoemulsion is provided.
- an adjuvant composition for enhancing cellular immunity as well as humoral immunity and a vaccine composition comprising an antigen.
- a method for producing a nanoemulsion comprising a.
- Nanoemulsions comprising an oil layer comprising an imidazoquinoline-based toll-like receptor 7 or 8 agonist and an oil according to the present invention are useful for the prevention of infectious diseases, therapeutic vaccines and immune chemotherapy. It is possible to provide the vaccine adjuvant in the form of emulsion used for activation, and also to disperse imidazoquinoline-based materials stably in an oil such as squalene using a dispersion medium material, and finally to prepare the oil layer thus prepared in emulsion form. By the preparation, it is possible to provide a vaccine adjuvant using imidazoquinoline series material that is poorly soluble in most organic solvents and aqueous solutions.
- the adjuvant in the form of a nanoemulsion of the present invention when used as a vaccine in combination with an antigen, has the effect of simultaneously improving humoral and cellular immunity.
- the nanoemulsion comprising an oil layer comprising an imidazoquinoline-based toll-like receptor 7 or 8 agonist and an oil according to the present invention is a lipophilic imidazoquinoline-based toll-like receptor agonist. Because of the controlled release behavior characteristics from the inner oil layer to the aqueous solution layer, it is released slowly in the body, thereby improving the cellular immune effect, while solving the systemic toxicity problem.
- FIG. 1 is a schematic diagram showing the structure of a nanoemulsion adjuvant composition composed of an imidazoquinoline-based toll-like receptor agonist, a dispersion mediator material, an oil, a surfactant, and an immunoactivating agent component according to one embodiment of the invention.
- FIG. 2A illustrates data obtained by measuring the size and size distribution of a nanoemulsion (NE-IQ) including a nanoemulsion (NE) and an imidazoquinoline-based toll-like receptor agonist according to an embodiment of the present invention.
- Light Scattering Measurement data.
- Figure 2b is a data measuring the size and size distribution of the nanoemulsion (NE-IQ) comprising a nanoemulsion (NE) and imidazoquinoline-based toll-like receptor agonist according to an embodiment of the present invention, TEM (Transmission) Electron Microscopy) image (NE-IQ).
- Figure 3 shows the delivery and distribution in immune cells (BMDC: bone-marrow derived dendritic cell, BMMC: bone-marrow derived macrophage cell) of NE-IQ according to an embodiment of the present invention (NE-IQ (DID) , Lysotracker (FITC), where a is for BMDC and b is for BMMC.
- BMDC bone-marrow derived dendritic cell
- BMMC bone-marrow derived macrophage cell
- Figure 4 shows the concentration dependence of imiquimod (R837) of the expression level of cytokines associated with the maturation of immune cells after the treatment of NE-IQ according to an embodiment of the invention
- a is BMDC
- b is BMMC
- a is BMDC
- b is BMMC
- Figure 5 shows the concentration dependence of R837 of the surface marker expression rate survival rate associated with the maturation of immune cells after the treatment of NE-IQ according to an embodiment of the invention
- a is a BMDC
- b is a graph for BMMC.
- Figure 6 shows the effect on immune cell survival after 24, 48 hours after treatment with NE-IQ according to an embodiment of the invention
- a is a BMDC
- b is a graph for BMMC.
- Figure 7 shows the expression level of IFN-alpha, a type of Type I inteferon expressed after NE-IQ intramuscular injection.
- Figure 8 shows the enzyme immunoassay-IgG titer (3, 6, 9 weeks) of NE and NE-IQ against OVA (Ovalbumin) antigen in accordance with an embodiment of the present invention.
- Figure 9 shows the enzyme immunoassay-IgG1 titer (3, 6, 9 weeks) of NE and NE-IQ against OVA (Ovalbumin) antigen according to an embodiment of the present invention.
- Figure 10 shows the enzyme immunoassay of NE and NE-IQ-IgG2a titer (3, 6, 9 weeks) against OVA (Ovalbumin) antigen in accordance with an embodiment of the present invention.
- Figure 11 shows the enzyme immunoassay of NE and NE-IQ-IgG2a / IgG1 ratio (3, 6, 9 weeks) to the OVA (Ovalbumin) antigen according to an embodiment of the present invention.
- Figure 12 shows the Immunization schedule for measuring the CTL immune response that is activated after intramuscular injection of NE-IQ.
- Figure 13 shows the cellular immune-induced effects of NE and NE-IQ (IFN-gamma secretion by T cell activation) to the OVA (Ovalbumin) antigen according to an embodiment of the present invention.
- Figure 16 shows the results of measuring activation of CD3 (+) CD8 (+) T cells after immunization of NE-IQ in mice transplanted with B16F10 cancer cells.
- Fig. 17 shows the results of measuring activation of CD4 (+) IFN-gamma (+) cells after immunization of NE-IQ in mice transplanted with B16F10 cancer cells.
- Fig. 19 shows the results of confirming that antigens specific to cancer cell growth are inhibited after administration of a vaccine consisting of NE-IQ and ovalbumin antigen to mice transplanted with B16F10-OVA cancer cells.
- Figure 21 illustrates the cellular immune-induced effect (IFN-gamma secretion by T cell activation) of the NE-IQ series of vaccine adjuvant compositions for OVA (Ovalbumin) antigen in accordance with an embodiment of the present invention.
- the term "combination of these" included in the expression of the mark of the form of the word means one or more mixtures or combinations selected from the group consisting of the components described in the mark of the form of the mark, It means to include one or more selected from the group consisting of components.
- the present invention provides a nanoemulsion comprising an oil layer comprising an imidazoquinoline-based toll-like receptor 7 or 8 agonist and an oil.
- the imidazoquinoline-based toll-like receptor 7 or 8 agonist may be dispersed in a nanosized oil layer and coated with a surfactant, an immunoactivating material, or a combination thereof on the exterior of the emulsion. (FIG. 1).
- FIG. 1 is a schematic diagram of a nanoemulsion of the present invention, wherein an imidazoquinoline-based toll-like receptor 7 or 8 agonist is dispersed in an oil layer, and a spherical surface having a surfactant and / or an immunoactivating material coated thereon Form.
- the size of the nanoemulsion may be about 50 to 500 nm, for example about 50 to 300 nm, about 50 to 100 nm, about 70 to 500 nm, about 100 to 500 nm or about 100 to 200 nm.
- the nanoemulsion is a) dissolving an imidazoquinoline-based toll-like receptor 7 or 8 agonist in oil to prepare an oil solution; b) mixing at least one selected from the group consisting of a surfactant and an immunoactivating substance with the oil solution; And c) dispersing the mixed solution obtained in step b in an aqueous solution.
- the imidazoquinoline-based toll-like receptor 7 or 8 agonist may be dissolved in oil together with a mediator material to assist lipophilic interaction.
- the immunoactivating material may be used in admixture with a surfactant in the nanoemulsion preparation process, or after the nanoemulsion is prepared, may be additionally attached to the surface.
- the imidazoquinoline-based toll-like receptor 7 or 8 agonist and oil may be included in a weight ratio of 0.1: 100 to 1:50, for example, 1:20.
- the imidazoquinoline-based toll-like receptor 7 or 8 agonist is an immunoactivating substance and includes imiquimod, Resiquimod, Dactolisib, Gardiquimod, and Sumani. It may be selected from the group consisting of Sumanirole, motolimod, 3M-052, S-34240, 852, 854-A, and analogs thereof of 3M, for example, imiqui May be a mode.
- the oil may be selected from the group consisting of fish derived oils, animal derived oils, vegetable derived oils, tocopherols, mineral oils, castor oils and combinations thereof.
- the fish oil may be used without limitation as long as it is a metabolizable oil, and includes, for example, cod liver oil, shark liver oil, whale oil and the like.
- the shark liver oil contains squalene, a molecule known as 2,6,10,15,19,23-hexamethyl-2,6,10,14,18,22-tetracosahexaene, unsaturated terpene, squalene, Saturated analogs to squalane may also be included.
- the animal derived oil may include lard, tallow oil, tallow, and the like.
- the vegetable derived oil may be an oil derived from nuts, seeds, grains, and the like, and may include, for example, peanut oil, soybean oil, coconut oil, olive oil, and the like.
- the tocopherol may be tocopherol containing vitamin E.
- Various tocopherols are present ( ⁇ , ⁇ , ⁇ , ⁇ , ⁇ or ⁇ ), but ⁇ -tocopherol is generally used, for example DL- ⁇ -tocopherol can be used.
- the imidazoquinoline-based toll-like receptor 7 or 8 agonists may be solubilized and dispersed in oil by a mediator that is poorly soluble and aids in lipophilic interaction with the oil.
- the mediator may be, for example, myristic oleic acid, palmitoleic acid, sapienic acid, oleic acid, laidic acid, vacecic acid, linoleic acid, linoleicidic acid.
- the mediator material may be used in a weight ratio of 0.1: 10 to 10: 0.1 with the imidazoquinoline-based toll-like receptor 7 or 8 agonist and oil, for example 1: 5 to 5: 1.
- the surfactant is coated on the outside of the nanoemulsion so that the nanoemulsion can be dispersed in an aqueous solution, for example, polyoxyethylene sorbitan ester surfactant (Tween), in particular polysorbate 20 and polysorbate 80; Copolymers of ethylene oxide (EO), propylene oxide (PO), and / or butylene oxide (BO); Octosinol (eg, Triton X-100, or t-octylphenoxypolyethoxyethanol); (Octylphenoxy) polyethoxyethanol (IGEPAL CA-630 / NP-40); As phospholipid (phospholipid component), phosphatidylcholine (lecithin) phosphatidylethanolaniline, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, phosphatidic acid, sphingomyelin and cardiolipin; Nonylphenol ethoxylates
- the surfactant may be a mixture of these surfactants, such as a Tween 80 / Span 85 mixture, and a combination of polyoxyethylene sorbitan ester and octosinol. Other useful combinations may include laureth 9, polyoxyethylene sorbitan esters and / or octosinol.
- the surfactant may be used in an amount of 0.001 to 20% by weight based on the total weight of the total nanoemulsion, for example, 0.01 to 1%, 0.001 to 0.1%, 0.005 to 0.02%; It may be used at a weight of 0.1 to 20%, 0.1 to 10%, 0.1 to 1% or about 0.5%.
- the additional immunoactivating material coated on the outside of the nanoemulsion serves to stimulate the proliferation, differentiation and activity of dendritic cells, T cells and B cells, and thus activated T cells promote differentiation into cytotoxic T cells and And cytokines, such as interferon-gamma, are involved in cellular immune responses.
- Such additional immunoactivating agents include, for example, toll-like receptor agonists (TLRs), saponins, antiviral peptides, inflammasome inducers, NOD ligands, CDS ligand (cytosolic DNA sensor ligand), stimulator of interferon genes (STING) ligand, cationic lipids (cationic lipids), and combinations thereof may include a material selected from the group consisting of, but is not limited thereto. have.
- TLRs toll-like receptor agonists
- saponins saponins
- antiviral peptides antiviral peptides
- inflammasome inducers NOD ligands
- CDS ligand cytosolic DNA sensor ligand
- STING stimulator of interferon genes
- cationic lipids cationic lipids
- combinations thereof may include a material selected from the group consisting of, but is not limited thereto. have.
- the toll-like receptor agonist may be a natural toll-like receptor agonist or a synthetic toll-like receptor agonist.
- the immunoactivating agent may comprise a combination of one or more toll-like receptor agonists, for example CL401 (dual TLR2 and TLR7 agonists) or CL429 (dual TLR2 and NOD2 agonists) alone or a combination thereof. It may include a combination, but is not limited thereto.
- the toll-like receptor agonist may be one that can cause a signaling response through TLR-1, for example tri-acylated lipopeptide (LP); Phenol-soluble modulins; Cobacterium tuberculosis (Mycobacterium tuberculosis) lipopeptide; S- (2,3-bis (palmitoyloxy)-(2-RS) -propyl) -N-palmitoyl- (R) -Cys- (S) -Ser- (S) -Lys (4) -OH ; Bacterial lipopeptides from Borrelia burgdorfei; Trihydrochloride (Pam3Cys) lipopeptides that mimic the acetylated amino termini of OspA lipopeptides; And one or more materials selected from the group consisting of combinations thereof, but is not limited thereto.
- LP tri-acylated lipopeptide
- Phenol-soluble modulins Cobacterium tubercul
- the toll-like receptor agonist may include a TLR-2 agonist, and may include, for example, Pam3Cys-Lip, but is not limited thereto.
- the toll-like agonist may include a TLR-3 agonist, and may include, for example, Poly (I: C), Poly (ICLC), Poly (IC12U), Ampligen, or the like as a polyish family.
- TLR-3 agonist may include, for example, Poly (I: C), Poly (ICLC), Poly (IC12U), Ampligen, or the like as a polyish family.
- ICLC Poly
- IC12U Poly (IC12U)
- Ampligen or the like as a polyish family.
- the present invention is not limited thereto.
- the toll-like agonist may be one comprising a TLR-4 agonist, for example, Shigella flexineri outer membrane protein preparation, AGP, CRX-527, MPLA, PHAD, 3D-PHAD, GLA, And one or more materials selected from the group consisting of combinations thereof, but is not limited thereto.
- TLR-4 agonist for example, Shigella flexineri outer membrane protein preparation, AGP, CRX-527, MPLA, PHAD, 3D-PHAD, GLA, And one or more materials selected from the group consisting of combinations thereof, but is not limited thereto.
- the toll-like agonist may include a TLR-5 agonist, and may include, for example, flagellin or a fragment thereof, but is not limited thereto.
- the toll-like agonist may be one comprising a TLR-7 agonist or a TLR-8 agonist, for example, an imidazoquinoline molecule such as imiquimod, R837, resquimod, or R848; VTX-2337; CRX642; Imidazoquinoline covalently bound to a phospholipid group or a phosphonolipid group; And one or more materials selected from the group consisting of combinations thereof, but is not limited thereto.
- the toll-like agonist may be one containing a TLR-9 agonist, for example, may include an immunostimulatory oligonucleotide, but is not limited thereto.
- the immunostimulatory oligonucleotides may include one or more CpG motifs, but are not limited thereto.
- the saponin may be selected from the group consisting of QS21, Quil A, QS7, QS17, ⁇ -eskin, Digitonin, and combinations thereof, but is not limited thereto.
- the antiviral peptide may include KLK, but is not limited thereto.
- the influxome inducer may be trehalose-6,6-dibehenate (TDB), but is not limited thereto.
- the NOD ligand may be M-TriLYS (NOD2 agonist-synthetic Muramil tripeptide) or NOD2 agonist (N-glycolylated muramyldipeptid), but is not limited thereto.
- M-TriLYS NOD2 agonist-synthetic Muramil tripeptide
- NOD2 agonist N-glycolylated muramyldipeptid
- the CDS ligand may be Poly (dA: dT), but is not limited thereto.
- the STING ligand may be cGAMP, di-AMP, or di-GMP, but is not limited thereto.
- the immuno-activator is Pam3Cys-Lip, Poly (I: C), CRX-527, MPLA (monophosphoryl lipid A), flagellin (flagellin), imiquimod, resquimod, CpG, QS21, M
- the cationic lipids are DC-cholesterol (3ß- [N- (N ', N'-dimethylaminoethane) -carbamoyl] cholesterol hydrochloride), DDA (dimethyldioctadecylammonium), DOTAP (1,2-dioleoyl-3-trimethylammonium-propane), DOTMA (1,2-di-O-octadecenyl-3-trimethylammonium propane), EPC (1,2-dimyristoleoyl-sn-glycero-3-ethylphosphocholine), MVL5 (N1- [2-((1S) -1- [ (3-aminopropyl) amino] -4- [di (3-amino-propyl) amino] butylcarboxamido) ethyl] -3,4-di [oleyloxy] -benzamide), DODAP (lipids1,2-dioleoyl-3
- the present invention also provides an adjuvant composition comprising the nanoemulsion according to the present invention and a vaccine composition comprising the adjuvant composition and the antigen according to the present invention.
- the antigen may be selected from the group consisting of proteins, recombinant proteins, glycoproteins, genes, peptides, polysaccharides, lipopolysaccharides, polynucleotides, cells, viruses and combinations thereof.
- the protein may include, for example, overalbumin, peptide, recombinant protein, subunit, split protein antigen.
- the gene may comprise DNA or mRNA antigens, and the peptide may comprise peptide antigens specific for cancer cells or viruses.
- the cells may include, for example, dendritic cells, cancer cells and cancer cell derived lysates, and the virus may include, for example, influenza, highly pathogenic influenza.
- the adjuvant composition or vaccine composition may comprise one or more pharmaceutically acceptable carriers or diluents in addition to pharmaceutically effective amounts of nanoemulsions and / or antigens.
- the term “pharmaceutically effective amount” refers to an amount sufficient to allow the physiologically active ingredient to be administered to an animal or human to exhibit the desired physiological or pharmacological activity. However, the pharmaceutically effective amount may be appropriately changed depending on the severity of symptoms, age, weight, health condition, sex, route of administration, and duration of treatment.
- pharmaceutically acceptable refers to a physiologically acceptable and, when administered to a human, usually does not cause gastrointestinal disorders, allergic reactions such as dizziness or the like.
- carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, Polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
- fillers, anti-coagulants, lubricants, wetting agents, fragrances, emulsifiers and preservatives may be further included.
- compositions of the present invention can be formulated using methods known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal, and can be formulated for various oral or parenteral administration. It may be formulated in a form.
- the formulations may be in the form of powders, granules, tablets, emulsions, syrups, aerosols, soft or hard gelatin capsules, sterile injectable solutions, sterile powders.
- composition according to the invention can be administered via several routes including oral, transdermal, subcutaneous, intravenous or intramuscular, the dosage of the active ingredient being determined by several factors such as the route of administration, the age, sex, weight and severity of the patient. It may be appropriately selected depending on.
- the composition of the present invention can be administered in parallel with known compounds that can enhance the desired effect.
- Squalene comprising imiquimod prepared as in Example 1 (5% v / v, Sigma Aldrich, USA), Tween 80 (0.5% v / v, Sigma Aldrich, USA) and Span 85 (0.5% v / v, Sigma-Aldrich, USA) was dissolved in 2 mL of phosphate buffer solution (PBS, 0.0067M PO4) and released to disperse completely in phosphate buffer solution (PBS) for 1 minute using an ultrasonic tip sonicator. Thereafter, the mixture was stirred for about 2 hours using a tube revolve and then stored in a 4 ° C. refrigerator until use.
- PBS phosphate buffer solution
- the size of the emulsion was analyzed by DLS (Dynamic Light Scattering, Otsuga, Japan). As a result of measuring DLS (Dynamic Light Scattering, Otsuga, Japan), the diameters were 106.16 ⁇ 5.4 and 148.54 ⁇ 18.5m (Fig. 2, Table 1).
- BMDCs Bone marrow-derived dendritic cells
- BMMCs bone marrow-derived macrophage cells
- NE-IQ squalene nanoemulsion
- BMDCs bone marrow-derived dendritic cells
- BMMCs bone marrow-derived macrophage
- NE-IQ in Figure 4 When treated, it was confirmed that the secretion of IL-6 and IL-12, which induce Th1 response, was increased, and the secretion of TNF- ⁇ and inflammatory cytokine IL-1 ⁇ , which induce apoptosis and tumor suppression, was also increased. It can be seen that the increase is more significant than the case without including the mode (Imiquimod) (R837).
- NE-IQ was applied to bone marrow-derived dendritic cells (BMDCs) and bone marrow-derived macrophage (BMMCs). After treatment, the cell proliferation rate was evaluated. In the proliferation rate of FIG. 6, an MTS assay kit (Cell Proliferation) assay for measuring mitochondrial activity was used. NE-IQ When treated, it was confirmed that both 24-hour and 48-hour increase in both types of immune cells was more than 10-fold higher than without imiquimod.
- mice C57BL / 6 (female 5-6 weeks old, orient) mice were used, and 10 ⁇ g of ovalbumin (OVA) and 25 ⁇ g of imiquimod (R837) were dissolved in 50 ⁇ L in a single dose. 24 hours after the vaccine was injected into the mice, the secretion amount of IFN- ⁇ at the muscle and lymph node areas was analyzed by ELISA test method. NE-IQ The treated experimental group was confirmed to increase the cytokine secretion than other controls (control using NE and Alum adjuvant) (Fig. 7). Imiquimod (R837) is known to increase the secretion of interferon (IFN) cytokines through stimulation of toll like receptor 7.
- IFN interferon
- mice C57BL / 6 (female 5-6 weeks old, orient) mice were used, and 100 ⁇ g of ovalbumin (OVA) and 45.5 ⁇ g of imiquimod (R837) were used in one dose, as in Example 2 above.
- OVA ovalbumin
- R837 imiquimod
- the prepared NE-IQ was dissolved in 100 ⁇ L and used.
- Enzyme immunoassay was analyzed to increase the humoral immune response as mice were injected with the vaccine.
- Humoral immune response was performed three times in total, and the orbital blood collection in the mice three weeks after the vaccination was completed to compare the production of immunoglobulin IgG and IgG subtypes IgG1 and IgG2a with the control (Fig. 8: IgG 9: IgG1, FIG. 10: IgG2a production amount).
- the amount of antibody production was increased in all cases when the vaccine was inoculated, in particular, the highest effect was observed in the vaccine using NE-IQ containing imiquimod as an adjuvant.
- the IgG2a / IgG1 value indicating the degree of cellular immune enhancement was found to be the highest value in the experimental group using NE-IQ as an adjuvant (FIG. 11). The reason seems to be due to the role of imiquimod loaded inside NE.
- Example 8 Evaluate the effect of NE-IQ on cancer cell proliferation
- Tumor healing ability was confirmed after administration of NE-IQ to intratumor injection using a C57BL / 6 mouse melanoma model.
- 1x105 melanoma cells (B16F10) were injected subcutaneously into the right thigh of five female 6-week-old mice, and 100 ⁇ l of five injections were performed five days later, and the control group was injected with PBS. Then, tumor volume was measured 2-3 times a week for 19 days after cancer cell administration.
- NE-IQ was administered after cancer cell injection, it was observed that tumor cell proliferation was significantly suppressed compared to the control group (FIG. 14).
- T cell activated IFN-gamma-secreting CD8 + T cells in NE-IQ group compared with the control group. It was confirmed to promote (Fig. 17, Fig. 18).
- a melanoma model (B16F10-OVA) expressing the peptide of obvalmin (Ovalbumin, OVA)
- a vaccine consisting of NE-IQ and obalbumin antigen in the same manner as in Figure 12, the antigen-specific This confirmed that the cancer cell suppression (Fig. 19).
- Another tumor model was used to confirm the cancer cell proliferation inhibitory effect of NE-IQ. Tumor healing ability was confirmed after administration of NE-IQ to intratumor injection using a lymphoma model (EG7-OVA) expressing C57BL / 6 mouse OVA antigen.
- 1x105 lymphoma cells (EG7-OVA) were injected subcutaneously into the right thigh of five 6-week-old female females, and 100 ⁇ l were injected five times at three-day intervals after 5 days, and the control group was injected with PBS. Then, tumor volume was measured 2-3 times a week for 19 days after cancer cell administration. As a result, when NE-IQ was administered after cancer cell injection, it was observed that tumor cell proliferation was significantly suppressed compared to the control group (FIG. 20).
- Example 9 Including one or more additional immunoactivating substances in NE-IQ Nano Emulsion Produce
- Nanoemulsions comprising one or more additional immunoactivating substances, such as MPLA, DDA, QS21, etc. in the NE-IQ nanoemulsion were prepared in the composition shown in Table 2.
- Example 9-1 NE-IQ-1 Adjuvant Manufacture: NE-IQ + DDA + MPLA
- DOPC (1,2-Dioleoyl-sn-glycero-3-phosphocholine, 1 mg / mL, Sigma Aldrich, USA), DDA (dimethyldioctadecylammonium bromide, 1 mg / mL, Sigma Aldrich, USA), cholesterol (Cholesterol 0.25 mg / mL , Sigma-Aldrich, USA), MPLA [monophosphoryl lipid a, 0.2 mg / mL and yorki polar lipids (USA)] were dissolved in 1 mL of ethanol. After transferring the solution to a round flask, the ethanol was completely evaporated using a rotary evaporator to form a thin-film form.
- the dispersion solution was transferred to a 4 mL vial and released using a sonicator for 1 minute to disperse the lipid membrane completely in phosphate buffer (PBS) for 1 minute. Then, the mixture was stirred for about 2 hours using a tube revolve and then stored in a 4 ° C. refrigerator until use.
- PBS phosphate buffer
- Example 9-2 NE-IQ-2 Adjuvant Manufacture: NE-IQ + MPLA + QS21
- DOPC 1,2-Dioleoyl-sn-glycero-3-phosphocholine, 1 mg / mL, Sigma-Aldrich, USA
- MPLA 0.2 mg / mL, yorki polar lipids (United States)
- saponin QS21 , 0.2 mg / mL
- cholesterol Choesterol 0.25 mg / mL, Sigma Aldrich, USA
- Example 9-3 NE-IQ-3 Adjuvant Manufacture: NE-IQ + Pam3Cys -Lip + QS21
- DOPC (1,2-Dioleoyl-sn-glycero-3-phosphocholine, 1 mg / mL, Sigma-Aldrich, USA), Pam3Cys-Lip (0.2 mg / mL, Invivo Gen, USA), QS21 (QS21, 0.2 mg / mL ) was dissolved in 1 mL of ethanol. The solution was transferred to a round flask and ethanol was completely evaporated using a rotary concentrator to form a thin lipid membrane. NE-IQ (Pam3Cys-Lip + QS21) adjuvant was then prepared using the same method as in Example 3.
- DOPC (1,2-Dioleoyl-sn-glycero-3-phosphocholine, 1 mg / mL, Sigma Aldrich, USA), DDA (dimethyldioctadecylammonium bromide, 1 mg / mL, Sigma Aldrich, USA), c-di-AMP (2 mg, Invivo Gen, San Diego, USA), cholesterol (0.25 mg / mL, Sigma Aldrich, USA) were dissolved in 1 mL of ethanol. The solution was transferred to a round flask and ethanol was completely evaporated using a rotary concentrator to form a thin lipid membrane. NE-IQ (DDA + STING (cyclic DNA)) was then prepared using the same method as in Example 3.
- DOPC (1,2-Dioleoyl-sn-glycero-3-phosphocholine, 1 mg / mL, Sigma Aldrich, USA), DDA (dimethyldioctadecylammonium bromide, 1 mg / mL, Sigma Aldrich, USA), cholesterol (0.25 mg / mL, Sigma-Aldrich, USA) was dissolved in 1 mL of ethanol. The solution was transferred to a round flask and ethanol was completely evaporated using a rotary concentrator to form a thin lipid membrane.
- soybean oil (2.5% v / v, Sigma-Aldrich, USA) and Tween (1% v /) containing R837 prepared using the same preparation method as Example 1, except that soybean oil was used instead of squalene.
- phosphate buffer solution PBS, 0.0067M PO4
- the lipid membrane was dispersed in the solution at 600 rpm for 30 minutes at 60 ° C. using a stirrer.
- the dispersed solution was transferred to a 4 mL vial and released using a sonicator for 1 minute to completely disperse the lipid membrane in phosphate buffer (PBS).
- Poly (I: C) (2 mg / mL. Invivogen, USA) was dissolved in phosphate buffer solution (0.0067 M PO4), mixed with the nanoemulsion in a 1: 1 volume ratio, and then stirred for 2 hours. It was stored in a 4 °C refrigerator until.
- DOPC (1,2-Dioleoyl-sn-glycero-3-phosphocholine, 1 mg / mL, Sigma Aldrich, USA), DDA (dimethyldioctadecylammonium bromide, 1 mg / mL, Sigma Aldrich, USA), cholesterol (0.25 mg / mL, Sigma-Aldrich, USA) was dissolved in 1 mL of ethanol. The solution was transferred to a round flask and ethanol was completely evaporated using a rotary concentrator to form a thin lipid membrane.
- a phosphate buffer solution containing squalene (2.5% v / v, Sigma Aldrich, USA) and Tween (1% v / v) containing R837 prepared as in Example 1 (PBS, 0.0067M PO4)
- PBS phosphate buffer
- DOPC (1,2-Dioleoyl-sn-glycero-3-phosphocholine, 1 mg / mL, Sigma Aldrich, USA), DDA (dimethyldioctadecylammonium bromide, 1 mg / mL, Sigma Aldrich, USA), cholesterol (0.25 mg / mL, Sigma-Aldrich, USA) was dissolved in 1 mL of ethanol. The solution was transferred to a round flask and ethanol was completely evaporated using a rotary concentrator to form a thin lipid membrane.
- phosphate buffer solution PBS, 0.0067M PO4 containing squalene (2.5% v / v, Sigma Aldrich, USA) and Tween (1% v / v) comprising R837 prepared in Example 1
- the lipid membrane was dispersed in the solution at 600 rpm for 30 minutes at 60 ° C. using a stirrer.
- the dispersed solution was transferred to a 4 mL vial, and then released using a sonicator for 1 minute to completely disperse the lipid membrane in phosphate buffer (PBS).
- DOPC (1,2-Dioleoyl-sn-glycero-3-phosphocholine, 1 mg / mL, Sigma Aldrich, USA), DDA (dimethyldioctadecylammonium bromide, 1 mg / mL, Sigma Aldrich, USA), cholesterol (0.25 mg / mL, Sigma-Aldrich, USA) was dissolved in 1 mL of ethanol. The solution was transferred to a round flask and ethanol was completely evaporated using a rotary concentrator to form a thin lipid membrane.
- the lipid membrane was dispersed in the solution at 600 rpm for 30 minutes at 60 ° C. using a stirrer.
- the dispersed solution was transferred to a 4 mL vial and released using a sonicator for 1 minute to completely disperse lipids in phosphate buffer (PBS).
- CpG (2 mg / mL. Invivogen, USA) is dissolved in phosphate buffer solution (0.0067 M PO4), mixed with the nanoemulsion in a 1: 1 volume ratio, stirred for about 2 hours, and then placed in a 4 ° C refrigerator until use. Stored.
- the cellular immune response of T cells against the NE-IQ series vaccine adjuvant compositions prepared according to Examples 9-1 to 9-8 as described in Table 2 was measured using the same method as in Example 7. The results are shown in FIG. 21. As the additional immunoactivator was introduced, it was confirmed that the interferon-gamma (IFN- ⁇ ) secretion was rapidly improved.
- IFN- ⁇ interferon-gamma
- Nanoemulsions comprising an oil layer comprising an imidazoquinoline-based toll-like receptor 7 or 8 agonist and an oil according to the present invention are useful for the prevention of infectious diseases, therapeutic vaccines and immune chemotherapy. It is possible to provide the vaccine adjuvant in the form of emulsion used for activation, and also to disperse imidazoquinoline-based materials stably in an oil such as squalene using a dispersion medium material, and finally to prepare the oil layer thus prepared in emulsion form. By the preparation, it is possible to provide a vaccine adjuvant using imidazoquinoline series material that is poorly soluble in most organic solvents and aqueous solutions.
- the adjuvant in the form of a nanoemulsion of the present invention when used as a vaccine in combination with an antigen, has the effect of simultaneously improving humoral and cellular immunity.
- the nanoemulsion comprising an oil layer comprising an imidazoquinoline-based toll-like receptor 7 or 8 agonist and an oil according to the present invention is an lipophilic imidazoquinoline-based toll-like receptor agonist. Because of the controlled release behavior from the inner oil layer to the aqueous solution layer, it is released slowly in the body, thereby improving cellular immune effects, while solving the systemic toxicity problem.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (17)
- 이미다조퀴놀린계열 톨-유사 수용체 7 또는 8 아고니스트 및 오일을 포함하는 오일층을 포함하는 나노에멀젼.
- 제1항에 있어서, 상기 이미다조퀴놀린계열 톨-유사 수용체 7 또는 8 아고니스트는 나노 크기의 오일층 내부에 분산되어 있는 것을 특징으로 하는 나노에멀젼.
- 제2항에 있어서, 상기 계면활성제, 및 면역활성화 물질로 이루어지는 군으로부터 선택되는 하나 이상이 상기 오일층 외부에 코팅되어 있는 것을 특징으로 하는 나노에멀젼.
- 제1항에 있어서, 상기 이미다조퀴놀린계열 톨-유사 수용체 7 또는 8 아고니스트는 이미퀴모드(Imiquimod), 레시퀴모드(Resiquimod), 닥토리십(Dactolisib), 가디퀴모드(Gardiquimod), 수마니롤(Sumanirole), 모토리모드(motolimod), 및 이들의 유사체(derivatives)로 이루어진 군으로부터 선택되는 것을 특징으로 하는 나노에멀젼.
- 제1항에 있어서, 상기 오일은 어류 유래 오일, 동물성 유래 오일, 식물성 유래 오일, 토코페롤, 미네랄 오일, 및 케스터 오일로 이루어진 군으로부터 선택되는 것을 특징으로 하는 나노에멀젼.
- 제5항에 있어서, 상기 동물성 유래 오일은 스쿠알렌이고, 식물성 유래 오일은 올레산 인 것을 특징으로 하는 나노에멀젼.
- 제1항에 있어서, 상기 이미다조퀴놀린계열 톨-유사 수용체 7 또는 8 아고니스트와 오일은 0.1:100 내지 1:50의 중량비로 포함되는 것을 특징으로 하는 나노에멀젼.
- 제1항에 있어서, 상기 이미다조퀴놀린계열 톨-유사 수용체 7 또는 8 아고니스트와 오일 간에 친유성 상호작용을 도와주는 매개체 물질을 더 포함하는 것을 특징으로 하는 나노에멀젼.
- 제8항에 있어서, 상기 매개체 물질은 미리스트올레산, 팔미톨레산, 사피에닉산(Sapienic acid), 올레산, 엘라이딘산(Elaidic acid), 박센산(Vaccenic acid), 리놀레산, 리놀레에시딕산(Linoelaidic acid), 알파-리놀레산, 아라키돈산, 에티코사펜타엔산(Eicosapentaenoic acid), 에루크산(Erucic acid), 도코사헥사에노산(Docosahexaenonic acid), 카프릴산(Caprylic acid), 카프르산(Capric acid), 라우르산(Lauric acid), 미리스트산(Myristic acid), 팔미트산, 스테아르산, 아라크산(Arachidic acid), 베헨산(Behenic acid), 리그노세르산(Lignoceric acid), 및 세로트산(Cerotic acid)으로 이루어진 군으로부터 선택되는 것을 특징으로 하는 나노에멀젼.
- 제8항에 있어서, 상기 매개체 물질은 상기 이미다조퀴놀린계열 톨-유사 수용체 7 또는 8 아고니스트와 0.1:10 내지 10:0.1의 중량비로 포함되는 것을 특징으로 하는 나노에멀젼.
- 제3항에 있어서, 상기 계면활성제는폴리소르베이트 20 및 폴리소르베이트 80을 포함하는 폴리옥시에틸렌 소르비탄 에스테르 계면활성제(Tween);에틸렌 옥사이드(EO), 프로필렌 옥사이드(PO) 및 부틸렌 옥사이드(BO) 중 하나 이상을 포함하는 코폴리머;트리톤 X-100 및 t-옥틸페녹시폴리에톡시에탄올을 포함하는 옥토시놀;(옥틸페녹시)폴리에톡시에탄올;포스파티딜콜린(레시틴) 포스파티딜에탄올아닐린, 포스파티딜세린, 포스파티딜이노시톨, 포스파티딜글리세롤, 포스파티딘산, 스핑고미엘린 및 카디올리핀을 포함하는 포스포리피드;노닐페놀 에톡실레이트;트리에틸렌글리콜 모노라우릴 에테르를 포함하는 라우릴, 세틸 및 오레일 알코올로부터 유래된 폴리옥시에틸렌 패티 에테르; 및소르비탄 트리올레이트(Span85) 및 소르비탄 모노라우레이트를 포함하는 소르비탄 에스테르(SPAN)로 이루어진 군으로부터 선택되는 것을 특징으로 하는 나노에멀젼.
- 제3항에 있어서, 상기 면역활성화 물질은 톨-유사 수용체 아고니스트(toll-like receptor agonist, TLR), 사포닌, 항바이러스성 펩티드, 인플라머좀 인듀서(inflammasome inducer), NOD 리간드(NOD ligand), CDS 리간드(cytosolic DNA sensor ligand), STING(stimulator of interferon genes) 리간드, 및 양이온성 지질(cationic lipids) 로 이루어진 군으로부터 선택되는 것을 특징으로 하는 나노에멀젼.
- 제1항 내지 제12항 중 어느 한 항에 따른 나노에멀젼을 포함하는 아주번트 조성물.
- 제13항에 따른 아주번트 조성물, 및 항원을 포함하는 백신 조성물.
- 제14항에 있어서, 상기 항원은 단백질, 재조합 단백질, 당단백질, 유전자, 펩티드, 다당류, 지질다당류, 폴리뉴클레오티드, 세포, 및 바이러스로 이루어진 군으로부터 선택되는 것을 특징으로 하는 백신 조성물.
- a) 이미다조퀴놀린계열 톨-유사 수용체 7 또는 8 아고니스트를 오일에 용해시켜 오일용액을 제조하는 단계;b) 계면활성화제 및 면역활성화 물질로 이루어지는 군으로부터 선택되는 하나 이상을, 상기 오일용액과 혼합하는 단계; 및c) 상기 b 단계에서 수득한 혼합 용액을 수용액에 분산하는 단계;를 포함하는 나노에멀젼의 제조방법.
- 제16항에 있어서, 상기 오일용액 제조단계에서 이미다조퀴놀린계열 톨-유사 수용체 7 또는 8 아고니스트와 오일 간에 친유성 상호작용을 도와주는 매개체 물질을 오일에 더 용해 시키는 것을 특징으로 하는 나노에멀젼의 제조방법.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/485,544 US20200046831A1 (en) | 2017-02-13 | 2018-02-13 | Nanoemulsion comprising imidazoquinoline-based material and use thereof |
AU2018218721A AU2018218721A1 (en) | 2017-02-13 | 2018-02-13 | Nanoemulsion comprising imidazoquinoline-based material and use thereof |
EP18750674.6A EP3581170A4 (en) | 2017-02-13 | 2018-02-13 | NANOEMULSION CONSISTING OF A MATERIAL BASED ON IMIDAZOQUINOLINE AND ITS USE |
RU2019128380A RU2019128380A (ru) | 2017-02-13 | 2018-02-13 | Наноэмульсия, содержащая материал на основе имидазохинолина, и ее применение |
CN201880011728.0A CN110430868A (zh) | 2017-02-13 | 2018-02-13 | 包含基于咪唑并喹啉的材料的纳米乳液及其用途 |
JP2019542161A JP2020506938A (ja) | 2017-02-13 | 2018-02-13 | イミダゾキノリン系物質を含むナノエマルジョン及びその用途 |
CA3052940A CA3052940A1 (en) | 2017-02-13 | 2018-02-13 | Nanoemulsion comprising imidazoquinoline-based material and use thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20170019330 | 2017-02-13 | ||
KR10-2017-0019330 | 2017-02-13 | ||
KR10-2018-0016726 | 2018-02-12 | ||
KR1020180016726A KR101996538B1 (ko) | 2017-02-13 | 2018-02-12 | 이미다조퀴놀린계열 물질을 포함하는 나노에멀젼 및 이의 용도 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018147710A1 true WO2018147710A1 (ko) | 2018-08-16 |
Family
ID=63107648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2018/001891 WO2018147710A1 (ko) | 2017-02-13 | 2018-02-13 | 이미다조퀴놀린계열 물질을 포함하는 나노에멀젼 및 이의 용도 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2018147710A1 (ko) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022519705A (ja) * | 2019-02-08 | 2022-03-24 | リサーチ アンド ビジネス ファウンデーション ソンギュンクァン ユニバーシティ | Toll-like受容体7または8アゴニストとコレステロールの結合体およびその用途 |
US11433142B2 (en) | 2020-03-23 | 2022-09-06 | Hdt Bio Corp. | Compositions and methods for delivery of RNA-lipid nanoparticle complexes encoding for viral RNA polymerase region and protein antigen |
WO2023048760A1 (en) * | 2021-09-22 | 2023-03-30 | Hdt Bio Corp. | Rna vaccines against infectious diseases |
US11679163B2 (en) | 2019-09-20 | 2023-06-20 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110009157A (ko) * | 2008-04-16 | 2011-01-27 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
-
2018
- 2018-02-13 WO PCT/KR2018/001891 patent/WO2018147710A1/ko active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110009157A (ko) * | 2008-04-16 | 2011-01-27 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
Non-Patent Citations (4)
Title |
---|
BACHELDER, ERIC M. ET AL.: "In Vitro Analysis of Acetalated Dextran Microparticles as a Potent Delivery Platform for Vaccine Adjuvants", MOLECULAR PHARMACEUTICS, vol. 7, no. 3, 2010, pages 826 - 835, XP055537339 * |
CHEN, QIAN ET AL.: "Photothermal Therapy with Immune-adjuvant Nanoparticles Together with Checkpoint Blockade For Effective Cancer Immunotherapy", NATURE COMMUNICATIONS, vol. 7, 21 October 2016 (2016-10-21), pages 1 - 13, XP055537345 * |
HEO, MIN BEOM ET AL.: "Programmed Nanoparticles for Combined Immunomodulation, Antigen Presentation and Tracking of imminunotherapeutic Cells", BIOMATERIALS, vol. 35, 2014, pages 590 - 600, XP028762522 * |
LIN, WENJING ET AL.: "Co-delivery of Imiquimod and Plasmid DNA via an Amphiphilic pH-responsive Star Polymer that Forms Unimolecular Micelles in Water", POLYMERS, vol. 8, 2016, pages 1 - 1 7, XP055537349 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022519705A (ja) * | 2019-02-08 | 2022-03-24 | リサーチ アンド ビジネス ファウンデーション ソンギュンクァン ユニバーシティ | Toll-like受容体7または8アゴニストとコレステロールの結合体およびその用途 |
JP7287708B2 (ja) | 2019-02-08 | 2023-06-06 | プロジェニア インコーポレイテッド | Toll-like受容体7または8アゴニストとコレステロールの結合体およびその用途 |
US11679163B2 (en) | 2019-09-20 | 2023-06-20 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
US11534497B2 (en) | 2020-03-23 | 2022-12-27 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
US11559584B2 (en) | 2020-03-23 | 2023-01-24 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
US11648321B2 (en) | 2020-03-23 | 2023-05-16 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
US11648322B2 (en) | 2020-03-23 | 2023-05-16 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
US11654200B2 (en) | 2020-03-23 | 2023-05-23 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
US11458209B2 (en) | 2020-03-23 | 2022-10-04 | Hdt Bio Corp. | Compositions and methods for delivery of nucleic acid-lipid nanoparticle complexes encoding for viral RNA polymerase region and protein antigen |
US11433142B2 (en) | 2020-03-23 | 2022-09-06 | Hdt Bio Corp. | Compositions and methods for delivery of RNA-lipid nanoparticle complexes encoding for viral RNA polymerase region and protein antigen |
US11752218B2 (en) | 2020-03-23 | 2023-09-12 | Hdt Bio Corp. | Nucleic acid-small diameter and liquid core nanoparticle complexed compositions |
US11896677B2 (en) | 2020-03-23 | 2024-02-13 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
WO2023048760A1 (en) * | 2021-09-22 | 2023-03-30 | Hdt Bio Corp. | Rna vaccines against infectious diseases |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018147710A1 (ko) | 이미다조퀴놀린계열 물질을 포함하는 나노에멀젼 및 이의 용도 | |
KR101996538B1 (ko) | 이미다조퀴놀린계열 물질을 포함하는 나노에멀젼 및 이의 용도 | |
EP2341933B1 (en) | Lipidated imidazoquinoline derivatives | |
WO2013032207A1 (en) | Sustained-release lipid pre-concentrate of pharmacologically active substance and pharmaceutical composition comprising the same | |
JP2021531266A (ja) | 免疫応答を調節可能な金属含有製剤のための組成物および方法 | |
LV13498B (en) | Immunostimulant composition comprising at least one toll-like receptor 7 or toll-like receptor 8 agonist and a toll-like receptor 4 agonist | |
EP2590674A2 (en) | Compositions and methods for treating influenza | |
RU2733124C1 (ru) | Мультидоменная везикула, содержащая материал, контролирующий иммуносупрессивный фактор, способ её производства и содержащая её иммуномодулирующая композиция | |
US10973900B2 (en) | Dried composition | |
WO2021177679A1 (ko) | 병원균 외벽 성분 기반 생병원체 모방 나노 입자 및 그 제조 방법 | |
WO2003000232A2 (en) | Method for preparation of vesicles loaded with immunostimulator y oligodeoxynucleotides | |
WO2024025059A1 (ko) | 점막점착성-plga 나노입자 | |
KR0178422B1 (ko) | 한탄 바이러스의 펩타이드 항원을 함유하는 리포좀 | |
KR0173366B1 (ko) | B형 간염 바이러스의 펩타이드 항원을 함유하는 리포좀 | |
KR0173365B1 (ko) | C형 간염 바이러스의 펩타이드 항원을 함유하는 리포좀 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18750674 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019542161 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3052940 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018218721 Country of ref document: AU Date of ref document: 20180213 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2018750674 Country of ref document: EP |